<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Craigen, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Basil T Darras, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low  (<a class="graphic graphic_figure graphicRef81164" href="/z/d/graphic/81164.html" rel="external">figure 1</a>).</p><p>There are a number of inborn errors of glycogen metabolism that result from pathogenic variants in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number, according to the chronology of recognition of the responsible enzyme defect  (<a class="graphic graphic_table graphicRef54417" href="/z/d/graphic/54417.html" rel="external">table 1</a>). The age of onset varies from in utero to adulthood.</p><p>Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.</p><p class="bulletIndent1"><span class="glyph">●</span>The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See  <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen is the primary source of energy for high-intensity muscle activity by providing substrates for the generation of adenosine triphosphate (ATP). The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.</p><p></p><p>Glycogen branching enzyme (GBE) deficiency (GSD IV, MIM #232500) is also known as Andersen disease. This topic will review GBE deficiency (GSD IV). An overview of GSD is presented separately. (See  <a class="medical medical_review" href="/z/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>GBE (amylo [1,4 to 1,6] transglucosidase) catalyzes the attachment of short glucosyl chains to a naked peripheral chain of nascent glycogen  (<a class="graphic graphic_figure graphicRef81164" href="/z/d/graphic/81164.html" rel="external">figure 1</a>). Deficiency results in abnormal structure of glycogen (similar to amylopectin), known as polyglucosan, with fewer branch points and longer alpha-1-4-linked glucose polymers.</p><p class="headingAnchor" id="H3"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>GBE deficiency is an autosomal recessive disorder caused by pathogenic variants in the <em>GBE1</em> gene, located at 3p14. Although the enzyme is broadly expressed, the specific mechanisms that account for the variable clinical presentations are uncertain. However, absent enzyme activity is associated with severe disease, while milder phenotypes have residual enzyme activity [<a href="#rid1">1</a>]. Multiple pathogenic variants of the GBE gene have been associated with the neuromuscular form of the disease [<a href="#rid2">2,3</a>]. Truncating <em>GBE1</em> pathogenic variants cause a spectrum of disease severity ranging from intrauterine hydrops to fatal perinatal hypotonia and cardiomyopathy, resulting in death during the first months of life [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1992285258"><span class="h2">Classic form</span><span class="headingEndMark"> — </span>Affected patients typically present in early infancy with hepatosplenomegaly and failure to thrive. Hypoglycemia is not a typical feature of GSD IV but may appear late in the course of the disease, when it is associated with cirrhosis, esophageal varices, and ascites. Hepatocellular carcinoma may develop in patients with progressive liver disease [<a href="#rid5">5</a>]. The disorder can be rapidly progressive, leading to terminal liver failure without transplantation [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3759531243"><span class="h2">Neuromuscular form</span><span class="headingEndMark"> — </span>The less common neuromuscular form of GSD IV is clinically and genetically heterogeneous. Four main phenotypic variants have been distinguished based on the age of onset [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A perinatal form with fetal akinesia deformation sequence (FADS) characterized by multiple congenital contractures, hydrops fetalis, cardiac dysfunction, and perinatal death [<a href="#rid4">4,7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A congenital form with congenital hypotonia, muscle atrophy, cardiomyopathy, and weakness and a rapidly deteriorating course with death in early infancy [<a href="#rid4">4,10-14</a>]. Severe congenital cases are almost uniformly associated with "null" mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A late-childhood form with skeletal myopathy or cardiomyopathy [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An adult form that can present as an isolated myopathy or cardiomyopathy or as adult polyglucosan body disease (APBD), a multisystem disorder [<a href="#rid17">17,18</a>]. These patients have symptoms and signs of upper and lower motor neuron involvement. In a review of 50 cases of APBD, the typical first manifestation was bladder incontinence, followed by gait disturbance and lower limb paresthesias [<a href="#rid19">19</a>]. Progressive dementia is seen in patients with APBD [<a href="#rid20">20</a>]. Some patients have an atypical form of APBD, with onset in early adulthood, a history of liver involvement in infancy, and a subacute relapsing-remitting course similar to multiple sclerosis [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">GBE activity ranges from 8 to 25 percent, depending upon the specific genetic defect [<a href="#rid17">17,22,23</a>]. Neuropathologic examination reveals accumulation of abnormal glycogen molecules called polyglucosan bodies (PBs) in the cortex (processes of neurons) and white matter (astrocytes and microglial cells) of the whole brain [<a href="#rid24">24</a>]. PBs also accumulate in the peripheral nervous system [<a href="#rid25">25</a>] and in muscle. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Most patients are of Ashkenazi Jewish heritage, but non-Jewish patients have been reported as well [<a href="#rid17">17,22</a>]. Thirty percent of cases were apparent symptomatic heterozygotes [<a href="#rid19">19</a>]. However, these patients were subsequently found to also have a deep intronic pathogenic variant that leads to abnormal ribonucleic acid (RNA) splicing [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnostic workup varies depending upon the presentation and age at onset and may include routine clinical laboratory testing, imaging, electrophysiologic tests, and functional assessments [<a href="#rid26">26</a>]. Liver biopsy shows excessive glycogen accumulation with a characteristic staining pattern. In addition to the normal-appearing glycogen arranged in alpha and beta particles, fibrillar aggregations of glycogen are detected by electron microscopy. Fibrosis and cirrhosis are invariably present in the classic form of the disease. The diagnosis is supported by absent branching enzyme activity in skin fibroblasts, muscle, or liver and confirmed by detection of biallelic pathogenic variants with analysis of the entire coding region of the GBE gene (<em>GBE1</em>) using gene panel testing or whole exome/genome sequencing [<a href="#rid26">26,27</a>]. In genetically confirmed cases, prenatal diagnosis can be performed accurately in subsequent pregnancies by analysis of deoxyribonucleic acid (DNA) from chorionic villi or cultured amniocytes [<a href="#rid28">28</a>]. Polyglucosan bodies (PBs) have also been detected in placenta at 25 and 35 weeks of gestation in two genetically confirmed cases, raising the possibility of prenatal diagnosis by histologic evaluation of placental biopsies [<a href="#rid29">29</a>].</p><p>In patients with neuromuscular disease, the serum creatine kinase level is usually elevated. Elevated chitotriosidase, a marker of activated macrophages that is also increased in various lysosomal diseases, has been observed in several patients [<a href="#rid30">30</a>]. Muscle biopsy reveals the storage of PBs that appear as periodic acid-Schiff (PAS) stain-positive material that resists digestion with diastase. The glycogen particles appear abnormal by electron microscopy, but they are often associated with normal beta particles. PBs are also observed in genetically distinct disorders, in particular deficiencies of the muscle isoform of glycogen synthase (GYS1), the autoglycosylating protein glycogenin-1 (GYG1) that serves as the building block for glycogen synthesis, and the ubiquitin ligase RBCK1. The progressive neurologic disorder, Lafora disease, also accumulates PBs [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>GSD IV is a multisystem disorder, and thus affected persons should be managed by a multidisciplinary team led by a clinician with expertise in this disorder. Clinical members should include a metabolic/medical geneticist or neurogeneticist and other specialists dictated by the disease manifestations [<a href="#rid26">26</a>]. No specific treatment is available. However, dietary management is potentially useful in patients with GBE deficiency. A high-protein, low-carbohydrate diet with frequent feeding designed to reduce polyglucosan body (PB) accumulation and ketosis is reported to improve liver function and growth in a subset of patients [<a href="#rid32">32</a>]. Liver transplantation has been performed with evidence of reduction in glycogen storage in both heart and skeletal muscle in some patients [<a href="#rid33">33,34</a>], as well as normalization of liver enzymes and blood glucose [<a href="#rid35">35</a>], but extrahepatic disease progression reported in other cases [<a href="#rid36">36</a>]. In an in vitro study, polyglucosan neurotoxicity caused by GBE deficiency was reversed with rapamycin, indicating potential therapeutic value of glycogen synthase inhibition for treating GSDs [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – Glycogen branching enzyme (GBE) deficiency (glycogen storage disease [GSD] IV, Andersen disease, MIM #232500) is an autosomal recessive disorder caused by pathogenic variants in the <em>GBE1</em> gene. It results in abnormal structure of glycogen. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic form</strong> – Affected patients typically present in early infancy with hepatosplenomegaly and failure to thrive. Hypoglycemia is not a typical feature of the disease. GBE deficiency is rapidly progressive, leading to terminal liver failure without transplantation. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular form</strong> – A less common neuromuscular form of GBE deficiency is clinically heterogeneous, with four main phenotypic variants, distinguished by age of onset (perinatal, congenital, late childhood, and adult). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is supported by absent or reduced branching enzyme activity in skin fibroblasts, muscle, or liver and confirmed by mutation analysis of the entire coding region of the <em>GBE1</em> gene, gene panel, or whole exome/genome sequencing testing. Deoxyribonucleic acid (DNA) testing is commercially available. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– No specific treatment is available, although dietary intervention may benefit a subset of patients. Liver transplantation has been performed with evidence of reduction in glycogen storage in heart and skeletal muscle. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bao Y, Kishnani P, Wu JY, Chen YT. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. J Clin Invest 1996; 97:941.</a></li><li><a class="nounderline abstract_t">Bruno C, van Diggelen OP, Cassandrini D, et al. Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV). Neurology 2004; 63:1053.</a></li><li><a class="nounderline abstract_t">Bruno C, Cassandrini D, Assereto S, et al. Neuromuscular forms of glycogen branching enzyme deficiency. Acta Myol 2007; 26:75.</a></li><li><a class="nounderline abstract_t">Nolte KW, Janecke AR, Vorgerd M, et al. Congenital type IV glycogenosis: the spectrum of pleomorphic polyglucosan bodies in muscle, nerve, and spinal cord with two novel mutations in the GBE1 gene. Acta Neuropathol 2008; 116:491.</a></li><li><a class="nounderline abstract_t">de Moor RA, Schweizer JJ, van Hoek B, et al. Hepatocellular carcinoma in glycogen storage disease type IV. Arch Dis Child 2000; 82:479.</a></li><li><a class="nounderline abstract_t">Moses SW, Parvari R. The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2002; 2:177.</a></li><li><a class="nounderline abstract_t">Raju GP, Li HC, Bali DS, et al. A case of congenital glycogen storage disease type IV with a novel GBE1 mutation. J Child Neurol 2008; 23:349.</a></li><li><a class="nounderline abstract_t">Sandhu T, Polan M, Yu Z, et al. Case of Neonatal Fatality from Neuromuscular Variant of Glycogen Storage Disease Type IV. JIMD Rep 2019; 45:51.</a></li><li><a class="nounderline abstract_t">Radhakrishnan P, Moirangthem A, Nayak SS, et al. Novel pathogenic variants in GBE1 causing fetal akinesia deformation sequence and severe neuromuscular form of glycogen storage disease type IV. Clin Dysmorphol 2019; 28:17.</a></li><li><a class="nounderline abstract_t">Tang TT, Segura AD, Chen YT, et al. Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis. Acta Neuropathol 1994; 87:531.</a></li><li><a class="nounderline abstract_t">Janecke AR, Dertinger S, Ketelsen UP, et al. Neonatal type IV glycogen storage disease associated with "null" mutations in glycogen branching enzyme 1. J Pediatr 2004; 145:705.</a></li><li><a class="nounderline abstract_t">Assereto S, van Diggelen OP, Diogo L, et al. Null mutations and lethal congenital form of glycogen storage disease type IV. Biochem Biophys Res Commun 2007; 361:445.</a></li><li><a class="nounderline abstract_t">Lamperti C, Salani S, Lucchiari S, et al. Neuropathological study of skeletal muscle, heart, liver, and brain in a neonatal form of glycogen storage disease type IV associated with a new mutation in GBE1 gene. J Inherit Metab Dis 2009; 32 Suppl 1:S161.</a></li><li><a class="nounderline abstract_t">Escobar LF, Wagner S, Tucker M, Wareham J. Neonatal presentation of lethal neuromuscular glycogen storage disease type IV. J Perinatol 2012; 32:810.</a></li><li><a class="nounderline abstract_t">Servidei S, Riepe RE, Langston C, et al. Severe cardiopathy in branching enzyme deficiency. J Pediatr 1987; 111:51.</a></li><li><a class="nounderline abstract_t">Das BB, Narkewicz MR, Sokol RJ, et al. Amylopectinosis disease isolated to the heart with normal glycogen branching enzyme activity and gene sequence. Pediatr Transplant 2005; 9:261.</a></li><li><a class="nounderline abstract_t">Bruno C, Servidei S, Shanske S, et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol 1993; 33:88.</a></li><li><a class="nounderline abstract_t">Ndugga-Kabuye MK, Maleszewski J, Chanprasert S, Smith KD. Glycogen storage disease type IV: dilated cardiomyopathy as the isolated initial presentation in an adult patient. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Mochel F, Schiffmann R, Steenweg ME, et al. Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol 2012; 72:433.</a></li><li><a class="nounderline abstract_t">Rifai Z, Klitzke M, Tawil R, et al. Dementia of adult polyglucosan body disease. Evidence of cortical and subcortical dysfunction. Arch Neurol 1994; 51:90.</a></li><li><a class="nounderline abstract_t">Paradas C, Akman HO, Ionete C, et al. Branching enzyme deficiency: expanding the clinical spectrum. JAMA Neurol 2014; 71:41.</a></li><li><a class="nounderline abstract_t">Akman HO, Kakhlon O, Coku J, et al. Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease. JAMA Neurol 2015; 72:441.</a></li><li><a class="nounderline abstract_t">Sampaolo S, Esposito T, Gianfrancesco F, et al. A novel GBE1 mutation and features of polyglucosan bodies autophagy in adult polyglucosan body disease. Neuromuscul Disord 2015; 25:247.</a></li><li><a class="nounderline abstract_t">Wierzba-Bobrowicz T, Lewandowska E, Stepień T, Modzelewska J. Immunohistochemical and ultrastructural changes in the brain in probable adult glycogenosis type IV: adult polyglucosan body disease. Folia Neuropathol 2008; 46:165.</a></li><li><a class="nounderline abstract_t">Massa R, Bruno C, Martorana A, et al. Adult polyglucosan body disease: proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene. Muscle Nerve 2008; 37:530.</a></li><li><a class="nounderline abstract_t">Koch RL, Soler-Alfonso C, Kiely BT, et al. Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource. Mol Genet Metab 2023; 138:107525.</a></li><li><a class="nounderline abstract_t">Schene IF, Korenke CG, Huidekoper HH, et al. Glycogen Storage Disease Type IV: A Rare Cause for Neuromuscular Disorders or Often Missed? JIMD Rep 2019; 45:99.</a></li><li><a class="nounderline abstract_t">Akman HO, Karadimas C, Gyftodimou Y, et al. Prenatal diagnosis of glycogen storage disease type IV. Prenat Diagn 2006; 26:951.</a></li><li><a class="nounderline abstract_t">Konstantinidou AE, Anninos H, Dertinger S, et al. Placental involvement in glycogen storage disease type IV. Placenta 2008; 29:378.</a></li><li><a class="nounderline abstract_t">Hizarcioglu-Gulsen H, Yuce A, Akcoren Z, et al. A Rare Cause of Elevated Chitotriosidase Activity: Glycogen Storage Disease Type IV. JIMD Rep 2014; 17:63.</a></li><li><a class="nounderline abstract_t">Hedberg-Oldfors C, Oldfors A. Polyglucosan storage myopathies. Mol Aspects Med 2015; 46:85.</a></li><li><a class="nounderline abstract_t">Derks TGJ, Peeks F, de Boer F, et al. The potential of dietary treatment in patients with glycogen storage disease type IV. J Inherit Metab Dis 2021; 44:693.</a></li><li><a class="nounderline abstract_t">Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999; 158 Suppl 2:S43.</a></li><li><a class="nounderline abstract_t">Selby R, Starzl TE, Yunis E, et al. Liver transplantation for type IV glycogen storage disease. N Engl J Med 1991; 324:39.</a></li><li><a class="nounderline abstract_t">Beyzaei Z, Shamsaeefar A, Kazemi K, et al. Liver transplantation in glycogen storage disease: a single-center experience. Orphanet J Rare Dis 2022; 17:127.</a></li><li><a class="nounderline abstract_t">Willot S, Marchand V, Rasquin A, et al. Systemic progression of type IV glycogen storage disease after liver transplantation. J Pediatr Gastroenterol Nutr 2010; 51:661.</a></li><li><a class="nounderline abstract_t">Kakhlon O, Glickstein H, Feinstein N, et al. Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase. J Neurochem 2013; 127:101.</a></li></ol></div><div id="topicVersionRevision">Topic 2937 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613547" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452297" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17915577" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neuromuscular forms of glycogen branching enzyme deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18661138" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital type IV glycogenosis: the spectrum of pleomorphic polyglucosan bodies in muscle, nerve, and spinal cord with two novel mutations in the GBE1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833181" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatocellular carcinoma in glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11949934" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230843" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A case of congenital glycogen storage disease type IV with a novel GBE1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30311141" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Case of Neonatal Fatality from Neuromuscular Variant of Glycogen Storage Disease Type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303820" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Novel pathogenic variants in GBE1 causing fetal akinesia deformation sequence and severe neuromuscular form of glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059607" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520786" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neonatal type IV glycogen storage disease associated with "null" mutations in glycogen branching enzyme 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662246" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Null mutations and lethal congenital form of glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357989" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neuropathological study of skeletal muscle, heart, liver, and brain in a neonatal form of glycogen storage disease type IV associated with a new mutation in GBE1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014386" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neonatal presentation of lethal neuromuscular glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3474393" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe cardiopathy in branching enzyme deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787805" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Amylopectinosis disease isolated to the heart with normal glycogen branching enzyme activity and gene sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8494336" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Glycogen branching enzyme deficiency in adult polyglucosan body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31527204" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Glycogen storage disease type IV: dilated cardiomyopathy as the isolated initial presentation in an adult patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dementia of adult polyglucosan body disease. Evidence of cortical and subcortical dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248152" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Branching enzyme deficiency: expanding the clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25665141" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A novel GBE1 mutation and features of polyglucosan bodies autophagy in adult polyglucosan body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18825592" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Immunohistochemical and ultrastructural changes in the brain in probable adult glycogenosis type IV: adult polyglucosan body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994551" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adult polyglucosan body disease: proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36796138" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30569318" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glycogen Storage Disease Type IV: A Rare Cause for Neuromuscular Disorders or Often Missed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16874838" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prenatal diagnosis of glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289670" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Placental involvement in glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Rare Cause of Elevated Chitotriosidase Activity: Glycogen Storage Disease Type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26278982" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Polyglucosan storage myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332610" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The potential of dietary treatment in patients with glycogen storage disease type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603098" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Liver transplantation for glycogen storage disease types I, III, and IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984162" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Liver transplantation for type IV glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313948" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Liver transplantation in glycogen storage disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20531024" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic progression of type IV glycogen storage disease after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607684" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
